| 摘要: |
| 目的采用Meta分析对阿尔茨海默症(AD)与脑脊液（CSF）中补体3（C3）水平的关联性进行评价，探讨CSF中C3水平变化对于AD的临床意义。方法计算机检索Pubmed、Embase、中国期刊网(CNKI)、万方数据库(WANFANGDATA)、中国科技期刊数据库(VIP)，并辅以文献追溯等方法收集2017年8月以前国内外公开发表的关于AD患者CSF中C3水平的研究文献，采用Revman4.2软件进行Meta分析。结果共纳入4篇合格文献，累计241例患者和362例健康对照组。AD患者CSF中C3水平高于对照组，其合并标准化均数差（SMD）值为0.39及其95%CI：(0.02~0.77)。结论CSF中C3水平是早期诊断AD的一个潜在生物标记分子，但其病因关联性仍有待于在人群中开展大样本、前瞻性对照研究。 |
| 关键词: 阿尔茨海默症 脑脊液 补体 3 Meta 分析 |
| DOI：10.12056/j.issn.1006-2785.2018.40.14.2017-2330 |
| 分类号: |
| 基金项目: |
|
| Cerebrospinal fluid complement 3 levels in Alzheimer's disease: a meta-analysis |
|
|
|
Hangzhou Seventh People's Hospital
|
| Abstract: |
| Objective To conduct a systematic review on the relationship between cerebrospinal fluid (CSF) complement 3 (C3) levels and Alzheimer's disease (AD)． Methods Studies about the CSF C3 levels in AD patients were searched in Pubmed, Embase, CNKI, WANGFANG DATA, and VIP. The method of tracing back was also used to found relevant
articles. Revman4.2 software was used to conduct the meta-analysis. Results Four articles with a total of 241 patients and 362 healthy controls were included in analysis. The CSF C3 levels in AD patients were higher than those in controls. The pooled standardized mean difference (SMD) and the 95% CI were 0.39 (0.02,0.77). Conclusion CSF C3 level might be a potential biomarker for early diagnosis of AD, but the etiologic relevance between AD and CSF C3 need to be further studied. |
| Key words: Alzheimer's disease Cerebrospinal fluid Complement 3 Meta-analysis |
